Model save

.gitattributes

@@ -33,3 +33,4 @@ saved_model/**/* filter=lfs diff=lfs merge=lfs -text
 *.zip filter=lfs diff=lfs merge=lfs -text
 *.zst filter=lfs diff=lfs merge=lfs -text
 *tfevents* filter=lfs diff=lfs merge=lfs -text
+tokenizer.json filter=lfs diff=lfs merge=lfs -text

1_Pooling/config.json

@@ -0,0 +1,10 @@
+{
+  "word_embedding_dimension": 384,
+  "pooling_mode_cls_token": true,
+  "pooling_mode_mean_tokens": false,
+  "pooling_mode_max_tokens": false,
+  "pooling_mode_mean_sqrt_len_tokens": false,
+  "pooling_mode_weightedmean_tokens": false,
+  "pooling_mode_lasttoken": false,
+  "include_prompt": true
+}

README.md

@@ -0,0 +1,784 @@
+---
+tags:
+- sentence-transformers
+- sentence-similarity
+- feature-extraction
+- generated_from_trainer
+- dataset_size:34441
+- loss:MultipleNegativesRankingLoss
+base_model: ibm-granite/granite-embedding-107m-multilingual
+widget:
+- source_sentence: inhibitors antiviral, antibacterial is as in with and Tzds. not
+    been combination with insulin. sitagliptin resulted an HbA of effects rate of
+    (upper tract and urinary (when (when combined with sulfonylurea), hypersensitivity
+    facial administered insulin agogue insulin may to be lowered to hypoglycemia.
+    is and to properties to sitagliptin tin. is use as with glimepiride, pioglitazone.
+    COMBINATION THERAPY—ORAL AGENTS & MEDICATION in Type 2 Mellitus Failure maintain
+    good over owing to a decrease beta-cell physical lean or increase ectopic the
+    manage- of type diabetes. required to glycemic Unless is a contraindication, be
+    initiated with a biguanide. If metformin agent or is added. drug be secret- incretin-based
+    therapy, amylin glucosi- given to sulfonylureas or insulin cost, include metformin,
+    other oral a noninsulin injectable and intensified insulin
+  sentences:
+  - inhibitors such as antiviral, antifungal, and certain antibacterial agents. Saxagliptin
+    is approved as monotherapy and in combination with biguanides, sulfonylureas,
+    and Tzds. It has not been studied in combination with insulin. During clinical
+    trials, mono- and combination therapy with sitagliptin resulted in an HbA 1c reduc-
+    tion in the range of 0.4–0.9%. Adverse effects include an increased rate of infections
+    (upper respiratory tract and urinary tract), headaches, peripheral edema (when
+    combined with a Tzd), hypoglycemia (when combined with a sulfonylurea), and hypersensitivity
+    reactions (urticaria, facial edema). The dose of a concurrently administered insulin
+    secret- agogue or insulin may need to be lowered to prevent hypoglycemia. Linagliptin
+    is the most recently introduced drug in this class and appears to have properties
+    similar to sitagliptin and saxaglip- tin. It is approved for use as monotherapy
+    and in combination with metformin, glimepiride, and pioglitazone. COMBINATION
+    THERAPY—ORAL ANTIDIABETIC AGENTS & INJECTABLE MEDICATION Combination Therapy in
+    Type 2 Diabetes Mellitus Failure to maintain a good response to therapy over the
+    long term owing to a progressive decrease in beta-cell mass, reduction in physical
+    activity, decline in lean body mass, or increase in ectopic fat deposition remains
+    a disconcerting problem in the manage- ment of type 2 diabetes. Multiple medications
+    may be required to achieve glycemic control. Unless there is a contraindication,
+    medical therapy should be initiated with a biguanide. If clinical failure occurs
+    with metformin monotherapy, a second agent or insulin is added. The second-line
+    drug can be an insulin secret- agogue, Tzd, incretin-based therapy, amylin analog,
+    or a glucosi- dase inhibitor; preference is given to sulfonylureas or insulin
+    because of cost, adverse effects, and safety concerns. Third-line therapy can
+    include metformin, multiple other oral medications, or a noninsulin injectable
+    and metformin and intensified insulin
+  - 'of the integrity of membranes in cells and organelles. A. Nervous System The
+    developing central nervous system of the fetus and young child is the most sensitive
+    target organ for lead’s toxic effect. Epidemiologic studies suggest that blood
+    lead concentrations even less than 5 mcg/dL may result in subclinical deficits
+    in neurocog- nitive function in lead-exposed young children, with no demon- strable
+    threshold for a “no effect” level. The dose response between TABLE 57–1 Toxicology
+    of selected arsenic, lead, and mercury compounds. Form Entering Body Major Route
+    of Absorption Distribution Major Clinical Effects Key Aspects of Mechanism Metabolism
+    and Elimination Arsenic Inorganic arsenic salts Gastrointestinal, respiratory
+    (all mucosal surfaces) Predominantly soft tissues (highest in liver, kidney).
+    Avidly bound in skin, hair, nails Cardiovascular: shock, arrhythmias. CNS: encephalopathy,
+    peripheral neuropathy. Gastroenteritis; pan- cytopenia; cancer (many sites) Inhibits
+    enzymes; interferes with oxidative phosphorylation; alters cell signaling, gene
+    expression Methylation. Renal (major); sweat and feces (minor) Lead Inorganic
+    lead oxides and salts Gastrointestinal, respiratory Soft tissues; redistributed
+    to skeleton (> 90% of adult body burden) CNS deficits; peripheral neuropathy;
+    ane- mia; nephropathy; hypertension; reproductive toxicity Inhibits enzymes; interferes
+    with essential cations; alters membrane structure Renal (major); feces and breast
+    milk (minor) Organic (tetraethyl lead) Skin, gastrointesti- nal, respiratory Soft
+    tissues, especially liver, CNS Encephalopathy Hepatic dealkylation (fast) → trialkyme-
+    tabolites (slow) → dissociation to lead Urine and feces (major); sweat (minor)
+    Mercury Elemental mercury Respiratory tract Soft tissues, especially kidney, CNS
+    CNS: tremor, behavioral (erethism); gingivo'
+  - '61. Glucocorticoids for gastrointestinal use: See Chapter 62. REFERENCES Alesci
+    S et al: Glucocorticoid-induced osteoporosis: From basic mechanisms to clinical
+    aspects. Neuroimmunomodulation 2005;12:1. Bamberger CM, Schulte HM, Chrousos GP:
+    Molecular determinants of gluco- corticoid receptor function and tissue sensitivity
+    to glucocorticoids. Endocr Rev 1996;17:245. Charmandari E, Kino T: Chrousos syndrome:
+    A seminal report, a phylogenetic enigma and the clinical implications of glucocorticoid
+    signaling changes. Eur J Clin Invest 2010;40:932. Charmandari E, Tsigos C, Chrousos
+    GP: Neuroendocrinology of stress. Ann Rev Physiol 2005;67:259. Chrousos GP: Stress
+    and disorders of the stress system. Nat Endocrinol Rev 2009;5:374. Chrousos GP,
+    Kino T: Glucocorticoid signaling in the cell: Expanding clinical implications
+    to complex human behavioral and somatic disorders. In: Glucocorticoids and mood:
+    Clinical manifestations, risk factors, and molecular mechanisms. Proc NY Acad
+    Sci 2009;1179:153. Elenkov IJ, Chrousos GP: Stress hormones, TH1/TH2 patterns,
+    pro/anti-in- flammatory cytokines and susceptibility to disease. Trends Endocrinol
+    Metab 1999;10:359. Elenkov IJ et al: Cytokine dysregulation, inflammation, and
+    wellbeing. Neuroimmunomodulation 2005;12:255. Franchimont D et al: Glucocorticoids
+    and inflammation revisited: The state of the art. Neuroimmunomodulation 2002–03;10:247.
+    Graber AL et al: Natural history of pituitary-adrenal recovery following long-term
+    suppression with corticosteroids. J Clin Endocrinol Metab 1965;25:11. Hochberg
+    Z, Pacak K, Chrousos GP: Endocrine withdrawal syndromes. Endocrine Rev 2003;24:523.
+    Kalantaridou S, Chrousos GP: Clinical review 148:'
+- source_sentence: Against Gram-Negative Carbapenems Cephalosporins Chloramphenicol
+    Daptomycin Tigecycline Oxazolidinones Penicillins Streptogramins Trimethoprim
+    TABLE 51–5 agents that dosage or are contraindicated patients hepatic Dosage Adjustment
+    in Impairment Renal Impairment Dosage Needed Hepatic Impairment Acyclovir, aztreonam,
+    carbapenems, clarithromycin, colistin, cycloserine, daptomycin, didanosine, ethionamide,
+    famciclovir, foscarnet, ganciclovir, penicillins,3 stavudine, telithromycin, tenofovir,
+    trimethoprim- Cidofovir, tetracyclines2 Amprenavir, atazanavir, erythromycin,
+    1Except 2Except doxycycline minocycline. 3Except antistaphylococcal penicillins
+    (eg, dicloxacillin). That Alter Antimicrobi
+  sentences:
+  - the body to colonize various organs in the process called metastasis. Such tumor
+    stem cells thus can express clonogenic (colony-forming) capability, and they are
+    characterized by chromosome abnormalities reflecting their genetic instability,
+    which leads to progressive selection of subclones that can survive more readily
+    in the multicellular environment of the host. This genetic instability also allows
+    them to become resistant to chemotherapy and radiotherapy. The invasive and metastatic
+    processes as well as a series of metabolic abnormalities associated with the cancer
+    result in tumor-related symptoms and eventual death of the patient unless the
+    neoplasm can be eradicated with treatment. 54 CAUSES OF CANCER The incidence,
+    geographic distribution, and behavior of specific types of cancer are related
+    to multiple factors, including sex, age, race, genetic predisposition, and exposure
+    to environmental car- cinogens. Of these factors, environmental exposure is probably
+    most important. Exposure to ionizing radiation has been well documented as a significant
+    risk factor for a number of cancers, including acute leukemias, thyroid cancer,
+    breast cancer, lung cancer, soft tissue sarcoma, and basal cell and squamous cell
+    skin cancers. Chemical carcinogens (particularly those in tobacco smoke) as well
+    as azo dyes, aflatoxins, asbestos, benzene, and radon have all been well documented
+    as leading to a wide range of human cancers. Several viruses have been implicated
+    in the etiology of various human cancers. For example, hepatitis B and hepatitis
+    C are asso- ciated with the development of hepatocellular cancer; HIV is associated
+    with Hodgkin’s and non-Hodgkin’s lymphomas; human papillomavirus is associated
+    with cervical cancer and head and neck cancer; and Ebstein-Barr virus is associated
+    with nasopharyn- geal cancer. Expression of virus-induced neoplasia may also depend
+    on additional host and environmental factors that modu- late the transformation
+    process. Cellular genes are known that are homologous to the transforming genes
+    of the retroviruses, a family
+  - Against Gram-Positive Cocci Against Gram-Negative Bacilli Aminoglycosides Aminoglycosides
+    Carbapenems Carbapenems Cephalosporins Chloramphenicol Chloramphenicol Quinolones
+    Clindamycin Rifampin Daptomycin Tetracyclines Glycopeptide antibiotics Tigecycline
+    Ketolides Macrolides Oxazolidinones Penicillins Quinolones Rifampin Streptogramins
+    Sulfonamides Tetracyclines Tigecycline Trimethoprim TABLE 51–5 Antimicrobial agents
+    that require dosage adjustment or are contraindicated in patients with renal or
+    hepatic impairment. Dosage Adjustment Needed in Renal Impairment Contraindicated
+    in Renal Impairment Dosage Adjustment Needed in Hepatic Impairment Acyclovir,
+    amantadine, aminoglycosides, aztreonam, carbapenems, cephalosporins,1 clarithromycin,
+    colistin, cycloserine, daptomycin, didanosine, emtricitabine, ethambutol, ethionamide,
+    famciclovir, fluconazole, flucytosine, foscarnet, ganciclovir, lamivudine, penicillins,3
+    pyrazinamide, quinolones, 4 rimantadine, stavudine, telavancin, telbivudine, telithromycin,
+    tenofovir, terbinafine, trimethoprim- sulfamethoxazole, valacyclovir, vancomycin,
+    zidovudine Cidofovir, methenamine, nalidixic acid, nitrofurantoin, sulfonamides
+    (long-acting), tetracyclines2 Amprenavir, atazanavir, chloram- phenicol, clindamycin,
+    erythromycin, fosamprenavir, indinavir, metronida- zole, rimantadine, tigecycline
+    1Except ceftriaxone. 2Except doxycycline and possibly minocycline. 3Except antistaphylococcal
+    penicillins (eg, nafcillin and dicloxacillin). 4Except moxifloxacin. Conditions
+    That Alter Antimicrobi
+  - host disease after allogeneic stem cell trans- plantation. Cyclosporine has also
+    proved useful in a variety of autoimmune disorders, including uveitis, rheumatoid
+    arthritis, psoriasis, and asthma. Its combination with newer agents is show- ing
+    considerable efficacy in clinical and experimental settings where effective and
+    less toxic immunosuppression is needed. Newer for- mulations of cyclosporine have
+    been developed that are improving patient compliance (smaller, better tasting
+    pills) and increasing bioavailability. Tacrolimus Tacrolimus (FK 506) is an immunosuppressant
+    macrolide antibi- otic produced by Streptomyces tsukubaensis. It is not chemically
+    related to cyclosporine, but their mechanisms of action are similar. Both drugs
+    bind to cytoplasmic peptidylprolyl isomerases that are abundant in all tissues.
+    While cyclosporine binds to cyclophilin, tacrolimus binds to the immunophilin
+    FK-binding protein (FKBP). Both complexes inhibit calcineurin, which is necessary
+    for the activation of the T-cell-specific transcription factor NF-AT. On a weight
+    basis, tacrolimus is 10–100 times more potent than cyclosporine in inhibiting
+    immune responses. Tacrolimus is utilized for the same indications as cyclosporine,
+    particularly in organ and stem cell transplantation. Multicenter studies in the
+    USA and in Europe indicate that both graft and patient survival are similar for
+    the two drugs. Tacrolimus has proved to be effective therapy for preventing rejection
+    in solid-organ transplant patients even after failure of standard rejection therapy,
+    including anti-T- cell antibodies. It is now considered a standard prophylactic
+    agent (usually in combination with methotrexate or mycophenolate mofetil) for
+    graft-versus-host disease. Tacrolimus can be administered orally or intravenously.
+    The half-life of the intravenous form is approximately 9–12 hours. Like cyclosporine,
+    tacrolimus is metabolized primarily by P450 enzymes in the liver, and there is
+    potential for drug interactions. The dosage is determined by trough blood level
+    at
+- source_sentence: Antiprotozoal 923 therapy many strains of P and is a of recommended
+    chemopro- for in malaria-endemic with chloroquine-resistant is a synthetic 4-quinoline
+    is related to quinine. It only be given orally because local with parenteral It
+    is absorbed, and peak reached 18 Mefloquine is extensively distrib- uted and eliminated
+    treat- ment The terminal elimination about 20 days, weekly dosing ing, steady-state
+    levels are over a weeks; this shortened beginning a with consecutive although
+    is stan- practice. slowly mainly the The can in the after of & Mefloquine has
+    P falciparum vivax, but not against The mechanism of action is to mefloquine from
+    areas. appears regions Mefloquine quinine with Clinical Uses A. Chemoprophylaxis
+    Mefloquine prophylaxis most
+  sentences:
+  - CHAPTER 52 Antiprotozoal Drugs 923 MEFLOQUINE Mefloquine is effective therapy
+    for many chloroquine-resistant strains of P falciparum and against other species.
+    Although toxicity is a concern, mefloquine is one of the recommended chemopro-
+    phylactic drugs for use in most malaria-endemic regions with chloroquine-resistant
+    strains. Chemistry & Pharmacokinetics Mefloquine hydrochloride is a synthetic
+    4-quinoline methanol that is chemically related to quinine. It can only be given
+    orally because severe local irritation occurs with parenteral use. It is well
+    absorbed, and peak plasma concentrations are reached in about 18 hours. Mefloquine
+    is highly protein-bound, extensively distrib- uted in tissues, and eliminated
+    slowly, allowing a single-dose treat- ment regimen. The terminal elimination half-life
+    is about 20 days, allowing weekly dosing for chemoprophylaxis. With weekly dos-
+    ing, steady-state drug levels are reached over a number of weeks; this interval
+    can be shortened to 4 days by beginning a course with three consecutive daily
+    doses of 250 mg, although this is not stan- dard practice. Mefloquine and acid
+    metabolites of the drug are slowly excreted, mainly in the feces. The drug can
+    be detected in the blood for months after the completion of therapy. Antimalarial
+    Action & Resistance Mefloquine has strong blood schizonticidal activity against
+    P falciparum and P vivax, but it is not active against hepatic stages or gametocytes.
+    The mechanism of action of mefloquine is unknown. Sporadic resistance to mefloquine
+    has been reported from many areas. At present, resistance appears to be uncommon
+    except in regions of Southeast Asia with high rates of multidrug resistance (especially
+    border areas of Thailand). Mefloquine resis- tance appears to be associated with
+    resistance to quinine and halofantrine but not with resistance to chloroquine.
+    Clinical Uses A. Chemoprophylaxis Mefloquine is effective in prophylaxis against
+    most strain
+  - 938 SECTION VIII Chemotherapeutic Drugs Clinical Uses Albendazole is administered
+    on an empty stomach when used against intraluminal parasites but with a fatty
+    meal when used against tissue parasites. A. Ascariasis, Trichuriasis, and Hookworm
+    and Pinworm Infections For adults and children older than 2 years of age with
+    ascariasis and hookworm infections, the treatment is a single dose of 400 mg TABLE
+    53–1 Drugs for the treatment of helminthic infections. 1 Infecting Organism Drug
+    of Choice Alternative Drugs Roundworms (nematodes) Ascaris lumbricoides (roundworm)
+    Albendazole or pyrantel pamoate or mebendazole Ivermectin, piperazine Trichuris
+    trichiura (whipworm) Mebendazole or albendazole Ivermectin Necator americanus
+    (hookworm); Ancylostoma duodenale (hookworm) Albendazole or mebendazole or pyrantel
+    pamoate Strongyloides stercoralis (threadworm) Ivermectin Albendazole or thiabendazole
+    Enterobius vermicularis (pinworm) Mebendazole or pyrantel pamoate Albendazole
+    Trichinella spiralis (trichinosis) Mebendazole or albendazole; add corticosteroids
+    for severe infection Trichostrongylus species Pyrantel pamoate or mebendazole
+    Albendazole Cutaneous larva migrans (creeping eruption) Albendazole or ivermectin
+    Thiabendazole (topical) Visceral larva migrans Albendazole Mebendazole Angiostrongylus
+    cantonensis Albendazole or mebendazole Wuchereria bancrofti (filariasis); Brugia
+    malayi (filariasis); tropical eosinophilia; Loa loa (loiasis) Diethylcarbamazine
+    Ivermectin Onchocerca volvulus (onchocerciasis) Ivermectin Dracunculus medinensis
+    (guinea worm) Metronidazole Thiabendazole or mebendazole Capillaria philippinensis
+    (intestinal capillariasis) Albendazole Mebendazole Flukes (trematodes) Schistosoma
+    haematobium (bilharziasis)
+  - safely and effectively combined with 5-FU-, irinotecan-, and oxaliplatin-based
+    chemotherapy in the treatment of metastatic colorectal cancer. Bevacizumab is
+    FDA approved as a first-line treatment for metastatic colorectal cancer in combination
+    with any intravenous fluoropyrimidine-contain- ing regimen and is now also approved
+    in combination with che- motherapy for metastatic non-small lung cancer and breast
+    cancer. One potential advantage of this antibody is that it does not appear to
+    exacerbate the toxicities typically observed with cytotoxic che- motherapy. The
+    main safety concerns associated with bevacizumab include hypertension, an increased
+    incidence of arterial throm- boembolic events (transient ischemic attack, stroke,
+    angina, and myocardial infarction), wound healing complications, gastrointes-
+    tinal perforations, and proteinuria. Sorafenib is a small molecule that inhibits
+    multiple receptor tyrosine kinases (RTKs), especially VEGF-R2 and VEGF-R3, platelet-derived
+    growth factor-β (PDGFR-β), and raf kinase. It was initially approved for advanced
+    renal cell cancer and is also approved for advanced hepatocellular cancer. Sunitinib
+    is similar to sorafenib in that it inhibits multiple RTKs, although the specific
+    types are somewhat different. They include PDGFR-α and PDGFR-β, VEGF-R1, VEGF-R2,
+    VEGF-R3, and c-kit. It is approved for the treatment of advanced renal cell cancer
+    and for the treatment of gastrointestinal stromal tumors (GIST) after disease
+    progression on or with intolerance to imatinib. Pazopanib is a small molecule
+    that inhibits multiple RTKs, espe- cially VEGF-R2 and VEGF-R3, PDGFR-β, and raf
+    kinase. This oral agent is approved for the treatment of advanced renal cell cancer.
+    Sorafenib, sunitinib, and pazopanib are metabolized in the liver by the CYP3A4
+    system, and elimination is primarily hepatic with excretion in feces. Each of
+    these agents has potential interac-
+- source_sentence: Endocrine is gland, increases phate reduce the enhanced feedback
+    regulation the effect PTH to calcium and reduce Likewise, and at levels the D
+    kidney increase amount produced. High reducing PTH works by FGF23 1,25(OH) 2 raises
+    phosphate, whereas 2 D has such is appropriate. 1,25(OH) D of on serum inhibitory
+    effect negative feedback patients producing 1,25(OH) loss feedback coupled with
+    impaired and intestinal calcium leads to hyperparathyroidism. The of 2 D inhibit
+    being exploited with analogs serum calcium their drugs are useful roidism accompanying
+    chronic disease in of primary 1,25(OH) also stimulates production completes negative
+    feedback loop inhibits 1,25(OH) production while promoting hypophosphatemia, which
+    turn production 1,25(OH) D production. SECONDARY HOMEOST
+  sentences:
+  - 774 SECTION VII Endocrine Drugs that is detected by the parathyroid gland, increases
+    in serum phos- phate levels reduce the ionized calcium, leading to enhanced PTH
+    secretion. Such feedback regulation is appropriate to the net effect of PTH to
+    raise serum calcium and reduce serum phosphate levels. Likewise, both calcium
+    and phosphate at high levels reduce the amount of 1,25(OH) 2 D produced by the
+    kidney and increase the amount of 24,25(OH) 2 D produced. High serum calcium works
+    directly and indirectly by reducing PTH secretion. High serum phosphate works
+    directly and indirectly by increasing FGF23 levels. Since 1,25(OH) 2 D raises
+    serum calcium and phosphate, whereas 24,25(OH) 2 D has less effect, such feedback
+    regulation is again appropriate. 1,25(OH) 2 D directly inhibits PTH secretion
+    (independent of its effect on serum calcium) by a direct inhibitory effect on
+    PTH gene transcription. This pro- vides yet another negative feedback loop. In
+    patients with chronic renal failure who frequently are deficient in producing
+    1,25(OH) 2 D, loss of this 1,25(OH) 2 D-mediated feedback loop coupled with impaired
+    phosphate excretion and intestinal calcium absorption often leads to secondary
+    hyperparathyroidism. The ability of 1,25(OH) 2 D to inhibit PTH secretion directly
+    is being exploited with calcitriol analogs that have less effect on serum calcium
+    because of their lesser effect on intestinal calcium absorption. Such drugs are
+    proving useful in the management of secondary hyperparathy- roidism accompanying
+    chronic kidney disease and may be useful in selected cases of primary hyperparathyroidism.
+    1,25(OH) 2 D also stimulates the production of FGF23. This completes the negative
+    feedback loop in that FGF23 inhibits 1,25(OH) 2 D production while promoting hypophosphatemia,
+    which in turn inhibits FGF23 production and stimulates 1,25(OH) 2 D production.
+    SECONDARY HORMONAL REGULATORS OF BONE MINERAL HOMEOST
+  - ke). Equine and ovine antivenoms are available for rattle- snake envenomations,
+    but only equine antivenom is available for coral snake bite. The ovine antivenom
+    is a Fab preparation and is less immunogenic than whole equine IgG antivenoms,
+    but retains the ability to neutralize the rattlesnake venom. MONOCLONAL ANTIBODIES
+    (MABs ) Recent advances in the ability to manipulate the genes of immu- noglobulins
+    have resulted in development of a wide array of humanized and chimeric monoclonal
+    antibodies directed against therapeutic targets. The only murine elements of humanized
+    monoclonal antibodies are the complementarity-determining regions in the variable
+    domains of immunoglobulin heavy and light chains. Complementarity-determining
+    regions are primarily responsible for the antigen-binding capacity of antibodies.
+    Chimeric antibodies typically contain antigen-binding murine variable regions
+    and human constant regions. The following are brief descriptions of the engineered
+    antibodies that have been approved by the FDA. Antitumor MABs Alemtuzumab is a
+    humanized IgG 1 with a kappa chain that binds to CD52 found on normal and malignant
+    B and T lymphocytes, NK cells, monocytes, macrophages, and a small population
+    of granulocytes. Currently, alemtuzumab is approved for the treatment of B-cell
+    chronic lymphocytic leukemia in patients who have been treated with alkylating
+    agents and have failed fludarabine therapy. Alemtuzumab appears to deplete leukemic
+    and normal cells by direct antibody-dependent lysis. Patients receiving this antibody
+    become lymphopenic and may also become neutro- penic, anemic, and thrombocytopenic.
+    As a result patients should be closely monitored for opportunistic infections
+    and hemato- logic toxicity. Bevacizumab is a humanized IgG 1 monoclonal antibody
+    that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF from
+    binding to its receptor, especially on endothelial cells. It is an antiangiogenic
+    drug that
+  - rier only when the meninges are inflamed. Concentrations in cerebrospinal fluid
+    are highly variable, ranging from 4% to 64% of serum levels in the setting of
+    meningeal inflammation. As with all antituberculous drugs, resistance to ethambutol
+    emerges rapidly when the drug is used alone. Therefore, ethambutol is always given
+    in combination with other antituberculous drugs. Ethambutol hydrochloride, 15–25
+    mg/kg, is usually given as a single daily dose in combination with isoniazid or
+    rifampin. The higher dose is recommended for treatment of tuberculous menin- gitis.
+    The dose of ethambutol is 50 mg/kg when a twice-weekly dosing schedule is used.
+    Adverse Reactions Hypersensitivity to ethambutol is rare. The most common serious
+    adverse event is retrobulbar neuritis, resulting in loss of visual acuity and
+    red-green color blindness. This dose-related adverse effect is more likely to
+    occur at dosages of 25 mg/kg/d continued for several months. At 15 mg/kg/d or
+    less, visual disturbances are very rare. Periodic visual acuity testing is desirable
+    if the 25 mg/kg/d dosage is used. Ethambutol is relatively contraindicated in
+    chil- dren too young to permit assessment of visual acuity and red- green color
+    discrimination. PYRAZINAMIDE Pyrazinamide (PZA) is a relative of nicotinamide.
+    It is stable and slightly soluble in water. It is inactive at neutral pH, but
+    at pH 5.5 it inhibits tubercle bacilli at concentrations of approximately 20 mcg/mL.
+    The drug is taken up by macrophages and exerts its activity against mycobacteria
+    residing within the acidic environ- ment of lysosomes. Pyrazinamide (PZA) N C
+    O NH2 N Mechanism of Action & Clinical Uses Pyrazinamide is converted to pyrazinoic
+    acid—the active form of the drug—by mycobacterial pyrazinamidase, which is encoded
+    by
+- source_sentence: Agents 49–1 Agents to or prevent herpes simplex virus and varicella-zoster
+    virus (VZV) Route Administration Use Recommended Dosage and Regimen Acyclovir1
+    First herpes 400 tid 5 times daily 7–10 days Recurrent genital herpes treatment
+    or 200 daily or 800 bid or 800 mg tid × days in the HIV-infected mg 3–5 daily
+    days in the HIV-infected mg times Orolabial herpes 400 mg 5 × 5 treatment 800
+    qid treatment mg 5 days Intravenous mg/kg Mucocutaneous herpes the host treatment
+    q8h × mg/kg × days HSV 10–20 Varicella or zoster in the immunosuppressed host
+    × Topical (5% cream) Herpes labialis covering times × 4 days First genital herpes
+    500 × Recurrent treatment × 1 Genital in bid Genital herpes herpes suppression
+    the mg bid 1500 mg Orolabial suppression 250-500 mg mg tid × 7 treatment 10 days
+    Recurrent treatment 500 days Genital in HIV-infected treatment 5–10 herpes herpes
+    suppression HIV
+  sentences:
+  - Primaquine is the drug of choice for the eradication of dormant liver forms of
+    P vivax and P ovale and can also be used for chemo- prophylaxis against all malarial
+    species. Chemistry & Pharmacokinetics Primaquine phosphate is a synthetic 8-aminoquinoline
+    ( Figure 52–2 ). The drug is well absorbed orally, reaching peak plasma levels
+    in
+  - CHAPTER 49 Antiviral Agents 865 TABLE 49–1 Agents to treat or prevent herpes simplex
+    virus (HSV) and varicella-zoster virus (VZV) infections. Route of Administration
+    Use Recommended Adult Dosage and Regimen Acyclovir1 Oral First episode genital
+    herpes treatment 400 mg tid or 200 mg 5 times daily × 7–10 days Recurrent genital
+    herpes treatment 400 mg tid or 200 mg 5 times daily or 800 mg bid × 3–5 days or
+    800 mg tid × 2 days Genital herpes in the HIV-infected host treatment 400 mg 3–5
+    times daily × 5–10 days Genital herpes suppression in the HIV-infected host 400–800
+    mg bid–tid Herpes proctitis treatment 400 mg 5 times daily until healed Orolabial
+    herpes treatment 400 mg 5 times daily × 5 days Varicella treatment (age ≥ 2 years)
+    800 mg qid × 5 days Zoster treatment 800 mg 5 times daily × 7–10 days Intravenous
+    Severe HSV treatment 5 mg/kg q8h × 7–10 days Mucocutaneous herpes in the immunocompromised
+    host treatment 10 mg/kg q8h × 7–14 days Herpes encephalitis treatment 10–15 mg/kg
+    q8h × 14–21 days Neonatal HSV infection treatment 10–20 mg/kg q8h × 14–21 days
+    Varicella or zoster in the immunosuppressed host treatment 10 mg/kg q8h × 7 days
+    Topical (5% cream) Herpes labialis treatment Thin film covering lesion 5 times
+    daily × 4 days Famciclovir1 Oral First episode genital herpes treatment 500 mg
+    tid × 5–10 days Recurrent genital herpes treatment 1000 mg bid × 1 day Genital
+    herpes in the HIV-infected host treatment 500 mg bid × 5–10 days Genital herpes
+    suppression 250 mg bid Genital herpes suppression in the HIV-infected host 500
+    mg bid Orolabial herpes treatment 1500 mg once Orolabial or genital herpes suppression
+    250-500 mg bid Zoster 500 mg tid × 7 days Valacyclovir1 Oral First episode genital
+    herpes treatment 1000 mg bid × 10 days Recurrent genital herpes treatment 500
+    mg bid × 3 days Genital herpes in the HIV-infected host treatment 500–1000 mg
+    bid × 5–10 days Genital herpes suppression 500–1000 mg once daily Genital herpes
+    suppression in the HIV
+  - 708 SECTION VII Endocrine Drugs marked adverse effects because there is a recovery
+    period between each dose. The transition to an alternate-day schedule can be made
+    after the disease process is under control. It should be done gradu- ally and
+    with additional supportive measures between doses. When selecting a drug for use
+    in large doses, a medium- or intermediate-acting synthetic steroid with little
+    mineralocorticoid effect is advisable. If possible, it should be given as a single
+    morning dose. C. Special Dosage Forms Local therapy, such as topical preparations
+    for skin disease, oph- thalmic forms for eye disease, intra-articular injections
+    for joint disease, inhaled steroids for asthma, and hydrocortisone enemas for
+    ulcerative colitis, provides a means of delivering large amounts of steroid to
+    the diseased tissue with reduced systemic effects. Beclomethasone dipropionate,
+    and several other glucocorti- coids—primarily budesonide, flunisolide, and mometasone
+    furoate, administered as aerosols—have been found to be extremely useful in the
+    treatment of asthma (see Chapter 20 ). Beclomethasone dipropionate, triamcinolone
+    acetonide, budes- onide, flunisolide, and mometasone furoate are available as
+    nasal sprays for the topical treatment of allergic rhinitis. They are effec- tive
+    at doses (one or two sprays one, two, or three times daily) that in most patients
+    result in plasma levels that are too low to influ- ence adrenal function or have
+    any other systemic effects. Corticosteroids incorporated in ointments, creams,
+    lotions, and sprays are used extensively in dermatology. These preparations are
+    discussed in more detail in Chapter 61 . MINERALOCORTICOIDS (ALDOSTERONE, DEOXYCORTICOSTERONE,
+    FLUDROCORTISONE) The most important mineralocorticoid in humans is aldosterone.
+    However, small amounts of deoxycorticosterone (DOC) are also formed and released.
+    Although the amount is normally insignifi- cant, DOC was of some importance therapeut
+pipeline_tag: sentence-similarity
+library_name: sentence-transformers
+---
+
+# SentenceTransformer based on ibm-granite/granite-embedding-107m-multilingual
+
+This is a [sentence-transformers](https://www.SBERT.net) model finetuned from [ibm-granite/granite-embedding-107m-multilingual](https://huggingface.co/ibm-granite/granite-embedding-107m-multilingual). It maps sentences & paragraphs to a 384-dimensional dense vector space and can be used for semantic textual similarity, semantic search, paraphrase mining, text classification, clustering, and more.
+
+## Model Details
+
+### Model Description
+- **Model Type:** Sentence Transformer
+- **Base model:** [ibm-granite/granite-embedding-107m-multilingual](https://huggingface.co/ibm-granite/granite-embedding-107m-multilingual) <!-- at revision 5c793ec061753b0d0816865e1af7db3f675d65af -->
+- **Maximum Sequence Length:** 512 tokens
+- **Output Dimensionality:** 384 dimensions
+- **Similarity Function:** Cosine Similarity
+<!-- - **Training Dataset:** Unknown -->
+<!-- - **Language:** Unknown -->
+<!-- - **License:** Unknown -->
+
+### Model Sources
+
+- **Documentation:** [Sentence Transformers Documentation](https://sbert.net)
+- **Repository:** [Sentence Transformers on GitHub](https://github.com/UKPLab/sentence-transformers)
+- **Hugging Face:** [Sentence Transformers on Hugging Face](https://huggingface.co/models?library=sentence-transformers)
+
+### Full Model Architecture
+
+```
+SentenceTransformer(
+  (0): Transformer({'max_seq_length': 512, 'do_lower_case': False}) with Transformer model: XLMRobertaModel 
+  (1): Pooling({'word_embedding_dimension': 384, 'pooling_mode_cls_token': True, 'pooling_mode_mean_tokens': False, 'pooling_mode_max_tokens': False, 'pooling_mode_mean_sqrt_len_tokens': False, 'pooling_mode_weightedmean_tokens': False, 'pooling_mode_lasttoken': False, 'include_prompt': True})
+  (2): Normalize()
+)
+```
+
+## Usage
+
+### Direct Usage (Sentence Transformers)
+
+First install the Sentence Transformers library:
+
+```bash
+pip install -U sentence-transformers
+```
+
+Then you can load this model and run inference.
+```python
+from sentence_transformers import SentenceTransformer
+
+# Download from the 🤗 Hub
+model = SentenceTransformer("RikoteMaster/embedder-granite")
+# Run inference
+sentences = [
+    'Agents 49–1 Agents to or prevent herpes simplex virus and varicella-zoster virus (VZV) Route Administration Use Recommended Dosage and Regimen Acyclovir1 First herpes 400 tid 5 times daily 7–10 days Recurrent genital herpes treatment or 200 daily or 800 bid or 800 mg tid × days in the HIV-infected mg 3–5 daily days in the HIV-infected mg times Orolabial herpes 400 mg 5 × 5 treatment 800 qid treatment mg 5 days Intravenous mg/kg Mucocutaneous herpes the host treatment q8h × mg/kg × days HSV 10–20 Varicella or zoster in the immunosuppressed host × Topical (5% cream) Herpes labialis covering times × 4 days First genital herpes 500 × Recurrent treatment × 1 Genital in bid Genital herpes herpes suppression the mg bid 1500 mg Orolabial suppression 250-500 mg mg tid × 7 treatment 10 days Recurrent treatment 500 days Genital in HIV-infected treatment 5–10 herpes herpes suppression HIV',
+    'CHAPTER 49 Antiviral Agents 865 TABLE 49–1 Agents to treat or prevent herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Route of Administration Use Recommended Adult Dosage and Regimen Acyclovir1 Oral First episode genital herpes treatment 400 mg tid or 200 mg 5 times daily × 7–10 days Recurrent genital herpes treatment 400 mg tid or 200 mg 5 times daily or 800 mg bid × 3–5 days or 800 mg tid × 2 days Genital herpes in the HIV-infected host treatment 400 mg 3–5 times daily × 5–10 days Genital herpes suppression in the HIV-infected host 400–800 mg bid–tid Herpes proctitis treatment 400 mg 5 times daily until healed Orolabial herpes treatment 400 mg 5 times daily × 5 days Varicella treatment (age ≥ 2 years) 800 mg qid × 5 days Zoster treatment 800 mg 5 times daily × 7–10 days Intravenous Severe HSV treatment 5 mg/kg q8h × 7–10 days Mucocutaneous herpes in the immunocompromised host treatment 10 mg/kg q8h × 7–14 days Herpes encephalitis treatment 10–15 mg/kg q8h × 14–21 days Neonatal HSV infection treatment 10–20 mg/kg q8h × 14–21 days Varicella or zoster in the immunosuppressed host treatment 10 mg/kg q8h × 7 days Topical (5% cream) Herpes labialis treatment Thin film covering lesion 5 times daily × 4 days Famciclovir1 Oral First episode genital herpes treatment 500 mg tid × 5–10 days Recurrent genital herpes treatment 1000 mg bid × 1 day Genital herpes in the HIV-infected host treatment 500 mg bid × 5–10 days Genital herpes suppression 250 mg bid Genital herpes suppression in the HIV-infected host 500 mg bid Orolabial herpes treatment 1500 mg once Orolabial or genital herpes suppression 250-500 mg bid Zoster 500 mg tid × 7 days Valacyclovir1 Oral First episode genital herpes treatment 1000 mg bid × 10 days Recurrent genital herpes treatment 500 mg bid × 3 days Genital herpes in the HIV-infected host treatment 500–1000 mg bid × 5–10 days Genital herpes suppression 500–1000 mg once daily Genital herpes suppression in the HIV',
+    '708 SECTION VII Endocrine Drugs marked adverse effects because there is a recovery period between each dose. The transition to an alternate-day schedule can be made after the disease process is under control. It should be done gradu- ally and with additional supportive measures between doses. When selecting a drug for use in large doses, a medium- or intermediate-acting synthetic steroid with little mineralocorticoid effect is advisable. If possible, it should be given as a single morning dose. C. Special Dosage Forms Local therapy, such as topical preparations for skin disease, oph- thalmic forms for eye disease, intra-articular injections for joint disease, inhaled steroids for asthma, and hydrocortisone enemas for ulcerative colitis, provides a means of delivering large amounts of steroid to the diseased tissue with reduced systemic effects. Beclomethasone dipropionate, and several other glucocorti- coids—primarily budesonide, flunisolide, and mometasone furoate, administered as aerosols—have been found to be extremely useful in the treatment of asthma (see Chapter 20 ). Beclomethasone dipropionate, triamcinolone acetonide, budes- onide, flunisolide, and mometasone furoate are available as nasal sprays for the topical treatment of allergic rhinitis. They are effec- tive at doses (one or two sprays one, two, or three times daily) that in most patients result in plasma levels that are too low to influ- ence adrenal function or have any other systemic effects. Corticosteroids incorporated in ointments, creams, lotions, and sprays are used extensively in dermatology. These preparations are discussed in more detail in Chapter 61 . MINERALOCORTICOIDS (ALDOSTERONE, DEOXYCORTICOSTERONE, FLUDROCORTISONE) The most important mineralocorticoid in humans is aldosterone. However, small amounts of deoxycorticosterone (DOC) are also formed and released. Although the amount is normally insignifi- cant, DOC was of some importance therapeut',
+]
+embeddings = model.encode(sentences)
+print(embeddings.shape)
+# [3, 384]
+
+# Get the similarity scores for the embeddings
+similarities = model.similarity(embeddings, embeddings)
+print(similarities.shape)
+# [3, 3]
+```
+
+<!--
+### Direct Usage (Transformers)
+
+<details><summary>Click to see the direct usage in Transformers</summary>
+
+</details>
+-->
+
+<!--
+### Downstream Usage (Sentence Transformers)
+
+You can finetune this model on your own dataset.
+
+<details><summary>Click to expand</summary>
+
+</details>
+-->
+
+<!--
+### Out-of-Scope Use
+
+*List how the model may foreseeably be misused and address what users ought not to do with the model.*
+-->
+
+<!--
+## Bias, Risks and Limitations
+
+*What are the known or foreseeable issues stemming from this model? You could also flag here known failure cases or weaknesses of the model.*
+-->
+
+<!--
+### Recommendations
+
+*What are recommendations with respect to the foreseeable issues? For example, filtering explicit content.*
+-->
+
+## Training Details
+
+### Training Dataset
+
+#### Unnamed Dataset
+
+* Size: 34,441 training samples
+* Columns: <code>anchor</code> and <code>positive</code>
+* Approximate statistics based on the first 1000 samples:
+  |         | anchor                                                                             | positive                                                                             |
+  |:--------|:-----------------------------------------------------------------------------------|:-------------------------------------------------------------------------------------|
+  | type    | string                                                                             | string                                                                               |
+  | details | <ul><li>min: 4 tokens</li><li>mean: 99.53 tokens</li><li>max: 279 tokens</li></ul> | <ul><li>min: 14 tokens</li><li>mean: 245.16 tokens</li><li>max: 512 tokens</li></ul> |
+* Samples:
+  | anchor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | positive                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
+  |:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
+  | <code>Advanced March 2022 Solving Notes by In this do the following: We Weight Update then use method to This is very fast solving these based on an 11 of in TCS, 2015” written Eggerling on notes Kaul that we last lecture. last lecture In lecture, we to the order to fairly smartly advice of the game-setting with days and N follows: . expert gives some advice: UP predicts, based on of the expert, or DOWN. with knowledge and aggregator’s the UP/DOWN outcome. observes the outcome suffers his was incorrect. by ε (the i w(1) i to 1. (All experts are equally the ning.) At t: based a weighted majority vote , . w(t) N ). • observing the cost vector, set w(t) i i (Discount Last lecture analyzed the case when ε 1/2. same proof Theorem sequence outcomes, duration and expert i #</code> | <code>Advanced Algorithms March 22, 2022 Lecture 9: Solving LPs using Multiplicative Weights Notes by Ola Svensson1 In this lecture we do the following: • We describe the Multiplicative Weight Update (actually Hedge) method. • We then use this method to solve covering LPs. • This is a very fast and simple (i.e., very attractive) method for solving these LPs approximately. These lecture notes are partly based on an updated version of “Lecture 11 of Topics in TCS, 2015” that were written by Vincent Eggerling and Simon Rodriguez and on the lecture notes by Shiva Kaul that we used in the last lecture. 1 Recall last lecture In the previous lecture, we saw how to use the weighted majority method in order to fairly smartly follow the advice of experts. Recall that the general game-setting with T days and N experts was as follows: For t = 1, . . . , T: 1. Each expert i ∈[N] gives some advice: UP or DOWN 2. Aggregator (you) predicts, based on the advice of the expert, UP or DOWN. 3. Adversary, with k...</code> |
+  | <code>analyzed the case when = same the following For any outcomes, T, and of of + O(log(N)/ε) These notes for the have not peer-reviewed and may contain inconsistent omit works.</code>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | <code>Last lecture we analyzed the case when ε = 1/2. The same proof gives the following Theorem 1 For any sequence of outcomes, duration T, and expert i ∈[N], # of WM mistakes ≤2(1 + ε) · (# of i’s mistakes) + O(log(N)/ε) . 1Disclaimer: These notes were written as notes for the lecturer. They have not been peer-reviewed and may contain inconsistent notation, typos, and omit citations of relevant works. 1</code>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
+  | <code>proof by defining function: each t . Φ(t) = i∈[N] i . We lower the Φ(T +1) using of of then bound terms bound: of goes a mistake initial weight is 1, Φ(T +1) = w(T +1) j ≥w(T +1) = (1 −ε)# of i’s mistakes bound: Every errs, at least half the experts (since weighted weights are (1 follows that down factor (1 WM ≤Φ(1) · WM = (1 WM for the equality that N initialized a weight of 1. The above give us (1 i’s mistakes ≤Φ(T WM . logs on then statement. 2 the game: for randomized strategies In you proved that instances for which weighted twice as as expert! is will to of making prediction (that the adversary then create side note this often is to following days and experts: 1, ,</code>                                                                                             | <code>Proof [Sketch] The proof was done by defining a potential function: for each t = 1, . . . , T + 1, let Φ(t) = X i∈[N] w(t) i . We now lower bound the “final” potential Φ(T +1) using the number of mistakes of i. We then upper bound it in terms of our number of mistakes. Lower bound: The weight of expert i goes down by a factor (1 −ε) for each mistake i does. As the initial weight of i is 1, Φ(T +1) = X j∈[N] w(T +1) j ≥w(T +1) i = (1 −ε)# of i’s mistakes . Upper bound: Every time WM errs, at least half the weight of the experts was wrong (since weighted majority was wrong). These weights are then decreased by (1 −ε). It follows that the potential goes down by at least a factor (1 −ε/2) every time WM errs. And so Φ(T +1) ≤Φ(1) · (1 −ε/2)# of WM mistakes = N · (1 −ε/2)# of WM mistakes , where for the equality we used that Φ(1) = N since each expert was initialized with a weight of 1. The above bounds give us (1 −ε)# of i’s mistakes ≤Φ(T +1) ≤N · (1 −ε/2)# of WM mistakes . Taking logs on b...</code> |
+* Loss: [<code>MultipleNegativesRankingLoss</code>](https://sbert.net/docs/package_reference/sentence_transformer/losses.html#multiplenegativesrankingloss) with these parameters:
+  ```json
+  {
+      "scale": 20.0,
+      "similarity_fct": "cos_sim"
+  }
+  ```
+
+### Evaluation Dataset
+
+#### Unnamed Dataset
+
+* Size: 3,827 evaluation samples
+* Columns: <code>anchor</code> and <code>positive</code>
+* Approximate statistics based on the first 1000 samples:
+  |         | anchor                                                                               | positive                                                                             |
+  |:--------|:-------------------------------------------------------------------------------------|:-------------------------------------------------------------------------------------|
+  | type    | string                                                                               | string                                                                               |
+  | details | <ul><li>min: 15 tokens</li><li>mean: 175.44 tokens</li><li>max: 258 tokens</li></ul> | <ul><li>min: 55 tokens</li><li>mean: 432.79 tokens</li><li>max: 512 tokens</li></ul> |
+* Samples:
+  | anchor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | positive                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
+  |:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
+  | <code>Adrenocorticosteroids & Adrenocortical Antagonists 707 hypertension occurs. or of hydrocortisone growth occurs in and have than steroid at equivalent in larger amounts, such and effects to glucocorticoid effects, sodium and loss potassium. and function, this leads to a hypochloremic alkalosis and eventually to pressure. In patients hypoproteinemia, renal or also In with even degrees to effects be minimized steroids, of potassium supplements. Adrenal administered more may treatment to appropriate at of stress for 24–48 severe to ten-fold dosage increases 48–72 trauma or major corti- costeroid dosage is to it should be slowly. be quite levels. may take 2–12 months hypothalamic-pituitary-adrenal function acceptably, cortisol levels to another months. The suppression is pituitary and treatment ACTH reduce time required the return function. If the in gluco- for certain disorder, the</code> | <code>CHAPTER 39 Adrenocorticosteroids & Adrenocortical Antagonists 707 hypertension also occurs. In dosages of 45 mg/m 2 /d or more of hydrocortisone or its equivalent, growth retardation occurs in children. Medium-, intermediate-, and long-acting glucocorticoids have greater growth-suppressing potency than the natural steroid at equivalent doses. When given in larger than physiologic amounts, steroids such as cortisone and hydrocortisone, which have mineralocorticoid effects in addition to glucocorticoid effects, cause some sodium and fluid retention and loss of potassium. In patients with normal cardiovas- cular and renal function, this leads to a hypokalemic, hypochloremic alkalosis and eventually to a rise in blood pressure. In patients with hypoproteinemia, renal disease, or liver disease, edema may also occur. In patients with heart disease, even small degrees of sodium retention may lead to heart failure. These effects can be minimized by using synthetic non-salt-retaining steroids, ...</code> |
+  | <code>is and treatment ACTH not the for of function. If too in corticoids a of the or in intensity. patients an patients Cushing’s also with These symptoms or ing, weight lethargy, joint or pain, postural many of symptoms reflect true deficiency, may occur presence normal even elevated cortisol gesting glucocorticoid Contraindications A. Special glucocorticoids carefully for development of retention peptic osteopo- rosis, should as as and administration alternate-day) should when therapeutic obtained schedule. on relatively low doses of such are intercurrent or acci- dents B. must with great patients with peptic heart heart cer- osteoporosis, or Selection of Dosage Schedule anti- mineralocorticoid duration action, cost, and dosage forms ( these should selecting the drug used. ACTH Adrenocortical Steroids In patients with used</code>                                                            | <code>is not a pituitary problem, and treatment with ACTH does not reduce the time required for the return of normal function. If the dosage is reduced too rapidly in patients receiving gluco- corticoids for a certain disorder, the symptoms of the disorder may reappear or increase in intensity. However, patients without an underlying disorder (eg, patients cured surgically of Cushing’s disease) also develop symptoms with rapid reductions in cortico- steroid levels. These symptoms include anorexia, nausea or vomit- ing, weight loss, lethargy, headache, fever, joint or muscle pain, and postural hypotension. Although many of these symptoms may reflect true glucocorticoid deficiency, they may also occur in the presence of normal or even elevated plasma cortisol levels, sug- gesting glucocorticoid dependence. Contraindications & Cautions A. Special Precautions Patients receiving glucocorticoids must be monitored carefully for the development of hyperglycemia, glycosuria, sodium retention with ede...</code> |
+  | <code>39–1 these factors be taken into drug be ACTH versus In with normal was used in production of similar effects. However, an the use a has in which was be were probably due amounts of corticosteroids the dosage B. Dosage the to be used, the physician the the of be required desired and of In some required for maintenance of the desired less the initial and the lowest dosage should gradually lowering the a small in is noted. When it is continuously elevated corticosteroid to suppress oral doses required. exists respect use of in inflammatory allergic same in a be effective than given in smaller doses in a Severe autoimmune vital organs must aggressively, and undertreatment is as To deposition immune and leukocytes 1 mg/kg/d predni- required initially. This dosage is main- tained the gradually are required alternate-day the may control in</code>                                              | <code>available ( Table 39–1 ), and these factors should be taken into account in selecting the drug to be used. A. ACTH versus Adrenocortical Steroids In patients with normal adrenals, ACTH was used in the past to induce the endogenous production of cortisol to obtain similar effects. However, except when an increase in androgens is desir- able, the use of ACTH as a therapeutic agent has been abandoned. Instances in which ACTH was claimed to be more effective than glucocorticoids were probably due to the administration of smaller amounts of corticosteroids than were produced by the dosage of ACTH. B. Dosage In determining the dosage regimen to be used, the physician must consider the seriousness of the disease, the amount of drug likely to be required to obtain the desired effect, and the duration of therapy. In some diseases, the amount required for maintenance of the desired therapeutic effect is less than the dose needed to obtain the initial effect, and the lowest possible dosage for th...</code> |
+* Loss: [<code>MultipleNegativesRankingLoss</code>](https://sbert.net/docs/package_reference/sentence_transformer/losses.html#multiplenegativesrankingloss) with these parameters:
+  ```json
+  {
+      "scale": 20.0,
+      "similarity_fct": "cos_sim"
+  }
+  ```
+
+### Training Hyperparameters
+#### Non-Default Hyperparameters
+
+- `eval_strategy`: steps
+- `per_device_train_batch_size`: 128
+- `per_device_eval_batch_size`: 128
+- `learning_rate`: 2e-05
+- `num_train_epochs`: 5
+- `warmup_ratio`: 0.1
+- `fp16`: True
+- `dataloader_drop_last`: True
+- `dataloader_num_workers`: 2
+- `load_best_model_at_end`: True
+- `push_to_hub`: True
+- `hub_model_id`: RikoteMaster/embedder-granite
+- `hub_strategy`: end
+- `hub_private_repo`: True
+
+#### All Hyperparameters
+<details><summary>Click to expand</summary>
+
+- `overwrite_output_dir`: False
+- `do_predict`: False
+- `eval_strategy`: steps
+- `prediction_loss_only`: True
+- `per_device_train_batch_size`: 128
+- `per_device_eval_batch_size`: 128
+- `per_gpu_train_batch_size`: None
+- `per_gpu_eval_batch_size`: None
+- `gradient_accumulation_steps`: 1
+- `eval_accumulation_steps`: None
+- `torch_empty_cache_steps`: None
+- `learning_rate`: 2e-05
+- `weight_decay`: 0.0
+- `adam_beta1`: 0.9
+- `adam_beta2`: 0.999
+- `adam_epsilon`: 1e-08
+- `max_grad_norm`: 1.0
+- `num_train_epochs`: 5
+- `max_steps`: -1
+- `lr_scheduler_type`: linear
+- `lr_scheduler_kwargs`: {}
+- `warmup_ratio`: 0.1
+- `warmup_steps`: 0
+- `log_level`: passive
+- `log_level_replica`: warning
+- `log_on_each_node`: True
+- `logging_nan_inf_filter`: True
+- `save_safetensors`: True
+- `save_on_each_node`: False
+- `save_only_model`: False
+- `restore_callback_states_from_checkpoint`: False
+- `no_cuda`: False
+- `use_cpu`: False
+- `use_mps_device`: False
+- `seed`: 42
+- `data_seed`: None
+- `jit_mode_eval`: False
+- `use_ipex`: False
+- `bf16`: False
+- `fp16`: True
+- `fp16_opt_level`: O1
+- `half_precision_backend`: auto
+- `bf16_full_eval`: False
+- `fp16_full_eval`: False
+- `tf32`: None
+- `local_rank`: 0
+- `ddp_backend`: None
+- `tpu_num_cores`: None
+- `tpu_metrics_debug`: False
+- `debug`: []
+- `dataloader_drop_last`: True
+- `dataloader_num_workers`: 2
+- `dataloader_prefetch_factor`: None
+- `past_index`: -1
+- `disable_tqdm`: False
+- `remove_unused_columns`: True
+- `label_names`: None
+- `load_best_model_at_end`: True
+- `ignore_data_skip`: False
+- `fsdp`: []
+- `fsdp_min_num_params`: 0
+- `fsdp_config`: {'min_num_params': 0, 'xla': False, 'xla_fsdp_v2': False, 'xla_fsdp_grad_ckpt': False}
+- `fsdp_transformer_layer_cls_to_wrap`: None
+- `accelerator_config`: {'split_batches': False, 'dispatch_batches': None, 'even_batches': True, 'use_seedable_sampler': True, 'non_blocking': False, 'gradient_accumulation_kwargs': None}
+- `deepspeed`: None
+- `label_smoothing_factor`: 0.0
+- `optim`: adamw_torch
+- `optim_args`: None
+- `adafactor`: False
+- `group_by_length`: False
+- `length_column_name`: length
+- `ddp_find_unused_parameters`: None
+- `ddp_bucket_cap_mb`: None
+- `ddp_broadcast_buffers`: False
+- `dataloader_pin_memory`: True
+- `dataloader_persistent_workers`: False
+- `skip_memory_metrics`: True
+- `use_legacy_prediction_loop`: False
+- `push_to_hub`: True
+- `resume_from_checkpoint`: None
+- `hub_model_id`: RikoteMaster/embedder-granite
+- `hub_strategy`: end
+- `hub_private_repo`: True
+- `hub_always_push`: False
+- `gradient_checkpointing`: False
+- `gradient_checkpointing_kwargs`: None
+- `include_inputs_for_metrics`: False
+- `include_for_metrics`: []
+- `eval_do_concat_batches`: True
+- `fp16_backend`: auto
+- `push_to_hub_model_id`: None
+- `push_to_hub_organization`: None
+- `mp_parameters`: 
+- `auto_find_batch_size`: False
+- `full_determinism`: False
+- `torchdynamo`: None
+- `ray_scope`: last
+- `ddp_timeout`: 1800
+- `torch_compile`: False
+- `torch_compile_backend`: None
+- `torch_compile_mode`: None
+- `include_tokens_per_second`: False
+- `include_num_input_tokens_seen`: False
+- `neftune_noise_alpha`: None
+- `optim_target_modules`: None
+- `batch_eval_metrics`: False
+- `eval_on_start`: False
+- `use_liger_kernel`: False
+- `eval_use_gather_object`: False
+- `average_tokens_across_devices`: False
+- `prompts`: None
+- `batch_sampler`: batch_sampler
+- `multi_dataset_batch_sampler`: proportional
+
+</details>
+
+### Training Logs
+| Epoch     | Step     | Training Loss | Validation Loss |
+|:---------:|:--------:|:-------------:|:---------------:|
+| 0.1859    | 50       | 0.3888        | -               |
+| 0.3717    | 100      | 0.1835        | -               |
+| 0.5576    | 150      | 0.0817        | -               |
+| 0.7435    | 200      | 0.0401        | 0.0351          |
+| 0.9294    | 250      | 0.0376        | -               |
+| 1.1152    | 300      | 0.0332        | -               |
+| 1.3011    | 350      | 0.028         | -               |
+| 1.4870    | 400      | 0.0285        | 0.0162          |
+| 1.6729    | 450      | 0.0246        | -               |
+| 1.8587    | 500      | 0.0239        | -               |
+| 2.0446    | 550      | 0.0241        | -               |
+| 2.2305    | 600      | 0.0237        | 0.0130          |
+| 2.4164    | 650      | 0.0222        | -               |
+| 2.6022    | 700      | 0.019         | -               |
+| 2.7881    | 750      | 0.0235        | -               |
+| 2.9740    | 800      | 0.0266        | 0.0120          |
+| 3.1599    | 850      | 0.0214        | -               |
+| 3.3457    | 900      | 0.024         | -               |
+| 3.5316    | 950      | 0.0249        | -               |
+| 3.7175    | 1000     | 0.0213        | 0.0113          |
+| 3.9033    | 1050     | 0.0233        | -               |
+| 4.0892    | 1100     | 0.0213        | -               |
+| 4.2751    | 1150     | 0.0202        | -               |
+| **4.461** | **1200** | **0.0227**    | **0.0109**      |
+| 4.6468    | 1250     | 0.0229        | -               |
+| 4.8327    | 1300     | 0.0196        | -               |
+
+* The bold row denotes the saved checkpoint.
+
+### Framework Versions
+- Python: 3.10.17
+- Sentence Transformers: 4.1.0
+- Transformers: 4.52.3
+- PyTorch: 2.7.0+cu126
+- Accelerate: 1.7.0
+- Datasets: 3.6.0
+- Tokenizers: 0.21.1
+
+## Citation
+
+### BibTeX
+
+#### Sentence Transformers
+```bibtex
+@inproceedings{reimers-2019-sentence-bert,
+    title = "Sentence-BERT: Sentence Embeddings using Siamese BERT-Networks",
+    author = "Reimers, Nils and Gurevych, Iryna",
+    booktitle = "Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing",
+    month = "11",
+    year = "2019",
+    publisher = "Association for Computational Linguistics",
+    url = "https://arxiv.org/abs/1908.10084",
+}
+```
+
+#### MultipleNegativesRankingLoss
+```bibtex
+@misc{henderson2017efficient,
+    title={Efficient Natural Language Response Suggestion for Smart Reply},
+    author={Matthew Henderson and Rami Al-Rfou and Brian Strope and Yun-hsuan Sung and Laszlo Lukacs and Ruiqi Guo and Sanjiv Kumar and Balint Miklos and Ray Kurzweil},
+    year={2017},
+    eprint={1705.00652},
+    archivePrefix={arXiv},
+    primaryClass={cs.CL}
+}
+```
+
+<!--
+## Glossary
+
+*Clearly define terms in order to be accessible across audiences.*
+-->
+
+<!--
+## Model Card Authors
+
+*Lists the people who create the model card, providing recognition and accountability for the detailed work that goes into its construction.*
+-->
+
+<!--
+## Model Card Contact
+
+*Provides a way for people who have updates to the Model Card, suggestions, or questions, to contact the Model Card authors.*
+-->

config.json

@@ -0,0 +1,26 @@
+{
+  "architectures": [
+    "XLMRobertaModel"
+  ],
+  "attention_probs_dropout_prob": 0.1,
+  "bos_token_id": 0,
+  "classifier_dropout": null,
+  "eos_token_id": 2,
+  "hidden_act": "gelu",
+  "hidden_dropout_prob": 0.1,
+  "hidden_size": 384,
+  "initializer_range": 0.02,
+  "intermediate_size": 1536,
+  "layer_norm_eps": 1e-12,
+  "max_position_embeddings": 514,
+  "model_type": "xlm-roberta",
+  "num_attention_heads": 12,
+  "num_hidden_layers": 6,
+  "pad_token_id": 1,
+  "position_embedding_type": "absolute",
+  "torch_dtype": "float32",
+  "transformers_version": "4.52.3",
+  "type_vocab_size": 2,
+  "use_cache": true,
+  "vocab_size": 250002
+}

config_sentence_transformers.json

@@ -0,0 +1,10 @@
+{
+  "__version__": {
+    "sentence_transformers": "4.1.0",
+    "transformers": "4.52.3",
+    "pytorch": "2.7.0+cu126"
+  },
+  "prompts": {},
+  "default_prompt_name": null,
+  "similarity_fn_name": "cosine"
+}

model.safetensors

@@ -0,0 +1,3 @@
+version https://git-lfs.github.com/spec/v1
+oid sha256:d63dc9c56fb09e54dc9a37bc41e80aad34770dc63a83a803d2e067c0ad9a7b40
+size 427988744

modules.json

@@ -0,0 +1,20 @@
+[
+  {
+    "idx": 0,
+    "name": "0",
+    "path": "",
+    "type": "sentence_transformers.models.Transformer"
+  },
+  {
+    "idx": 1,
+    "name": "1",
+    "path": "1_Pooling",
+    "type": "sentence_transformers.models.Pooling"
+  },
+  {
+    "idx": 2,
+    "name": "2",
+    "path": "2_Normalize",
+    "type": "sentence_transformers.models.Normalize"
+  }
+]

sentence_bert_config.json

@@ -0,0 +1,4 @@
+{
+  "max_seq_length": 512,
+  "do_lower_case": false
+}

special_tokens_map.json

@@ -0,0 +1,51 @@
+{
+  "bos_token": {
+    "content": "<s>",
+    "lstrip": false,
+    "normalized": false,
+    "rstrip": false,
+    "single_word": false
+  },
+  "cls_token": {
+    "content": "<s>",
+    "lstrip": false,
+    "normalized": false,
+    "rstrip": false,
+    "single_word": false
+  },
+  "eos_token": {
+    "content": "</s>",
+    "lstrip": false,
+    "normalized": false,
+    "rstrip": false,
+    "single_word": false
+  },
+  "mask_token": {
+    "content": "<mask>",
+    "lstrip": true,
+    "normalized": true,
+    "rstrip": false,
+    "single_word": false
+  },
+  "pad_token": {
+    "content": "<pad>",
+    "lstrip": false,
+    "normalized": false,
+    "rstrip": false,
+    "single_word": false
+  },
+  "sep_token": {
+    "content": "</s>",
+    "lstrip": false,
+    "normalized": false,
+    "rstrip": false,
+    "single_word": false
+  },
+  "unk_token": {
+    "content": "<unk>",
+    "lstrip": false,
+    "normalized": false,
+    "rstrip": false,
+    "single_word": false
+  }
+}

tokenizer.json

@@ -0,0 +1,3 @@
+version https://git-lfs.github.com/spec/v1
+oid sha256:4a8d0b7573869188be52cca17a27a84f3cfbc0a5536c28ee1eca82903e8c68c6
+size 17083051

tokenizer_config.json

@@ -0,0 +1,56 @@
+{
+  "added_tokens_decoder": {
+    "0": {
+      "content": "<s>",
+      "lstrip": false,
+      "normalized": false,
+      "rstrip": false,
+      "single_word": false,
+      "special": true
+    },
+    "1": {
+      "content": "<pad>",
+      "lstrip": false,
+      "normalized": false,
+      "rstrip": false,
+      "single_word": false,
+      "special": true
+    },
+    "2": {
+      "content": "</s>",
+      "lstrip": false,
+      "normalized": false,
+      "rstrip": false,
+      "single_word": false,
+      "special": true
+    },
+    "3": {
+      "content": "<unk>",
+      "lstrip": false,
+      "normalized": false,
+      "rstrip": false,
+      "single_word": false,
+      "special": true
+    },
+    "250001": {
+      "content": "<mask>",
+      "lstrip": true,
+      "normalized": true,
+      "rstrip": false,
+      "single_word": false,
+      "special": true
+    }
+  },
+  "bos_token": "<s>",
+  "clean_up_tokenization_spaces": false,
+  "cls_token": "<s>",
+  "eos_token": "</s>",
+  "extra_special_tokens": {},
+  "mask_token": "<mask>",
+  "model_max_length": 512,
+  "pad_token": "<pad>",
+  "sep_token": "</s>",
+  "sp_model_kwargs": {},
+  "tokenizer_class": "XLMRobertaTokenizer",
+  "unk_token": "<unk>"
+}

training_args.bin

@@ -0,0 +1,3 @@
+version https://git-lfs.github.com/spec/v1
+oid sha256:697607fc6ba410ea01355bf4a4f73d1fd301a942e36a7d759a3484ac0ef46a85
+size 6161

training_metadata.json

@@ -0,0 +1,28 @@
+{
+  "base_model": "sentence-transformers/all-MiniLM-L6-v2",
+  "training_corpus_size": 63474,
+  "training_examples": 63474,
+  "train_examples": 57126,
+  "validation_examples": 6348,
+  "validation_split": 0.1,
+  "chunk_size": 256,
+  "chunk_overlap": 50,
+  "batch_size": 128,
+  "epochs": 5,
+  "learning_rate": 2e-05,
+  "warmup_ratio": 0.1,
+  "early_stopping_patience": 5,
+  "eval_steps": 200,
+  "device": "cuda",
+  "training_api": "SentenceTransformers_v3+",
+  "loss_function": "MultipleNegativesRankingLoss",
+  "eval_strategy": "steps",
+  "fp16": true,
+  "save_strategy": "steps",
+  "save_steps": 200,
+  "logging_steps": 50,
+  "save_total_limit": 3,
+  "push_to_hub": true,
+  "hub_model_id": "RikoteMaster/retriever_pdf_and_books",
+  "hub_private": false
+}